In-depth guides
Plain-language guides examine recurring ideas, including claims about ibogaine and boxing culture, without treating anecdotes as proof.
Open Field 24 · Independent information
Guides, comparisons, and research summaries for people trying to separate the claims around ibogaine and alcohol from what evidence can actually support.
These are information services, not medical or clinical services. Ibogaine carries meaningful uncertainty and safety limits that should not be minimized.
Open Field 24 is an independent resource for people affected by alcohol use, families, and advocates seeking clear context on ibogaine claims and risks. Our approach to evidence and independence starts with a simple distinction: interest in a treatment idea is not the same as established effectiveness or safety.
For broader orientation, the main ibogaine and alcohol guide places common questions alongside risk clarity, preliminary findings, and the limits of what can responsibly be concluded. Alcohol use disorder is a recognized health condition, and the National Institute on Alcohol Abuse and Alcoholism’s overview of alcohol use disorder describes it as impaired ability to stop or control alcohol use despite adverse consequences.
Information offerings
Each service organizes a different part of a complicated subject: claims, terminology, research, and questions that deserve more than a simple answer.
Plain-language guides examine recurring ideas, including claims about ibogaine and boxing culture, without treating anecdotes as proof.
Research summaries separate biological hypotheses from human evidence, including discussions of ibogaine and neuroplasticity and the limits of early findings.
Focused explainers compare terms people encounter online, from ibogaine hydrochloride information to questions about what an ibogaine treatment involves. They provide context, not recommendations.
A claims check
“A compelling personal account settles the question.” Personal experiences matter, but they cannot establish safety, cause, or likely outcomes across different people.
Ibogaine has been associated with potentially serious cardiac effects; it is not a low-risk substance simply because some claims describe it as transformative.
What is the study design, who was screened out, what else occurred during care, and what outcomes were measured over time?
Safety context is not an obstacle to hopeful thinking. It is the condition for honest thinking.
The U.S. Food and Drug Administration notes that drug development and approval involve structured review of safety and effectiveness. This matters when online material presents ibogaine as settled. Explorers of ibogaine in MMA discussions or claims about a change in ego experience can use the same standard: distinguish a description of experience from evidence of a dependable treatment effect.
Questions people ask
No. Ibogaine is not an established treatment for alcohol use disorder. Interest and preliminary findings do not remove the need for careful evidence review, medical screening, and attention to serious risk.
It can organize claims, research summaries, safety context, comparisons, definitions, and questions that help people distinguish what is known from what remains uncertain. It cannot diagnose, screen, or provide treatment.
They are part of the public conversation. The goal is not to dismiss them, but to keep them in proportion: a personal report may be meaningful while still being insufficient evidence for a general claim about safety or effectiveness.
Keep the question open
Use the evidence review and safety material to examine claims with more care, especially when a simple answer feels most tempting.